

AGE|RECODE[®]

CLINICAL PROTOCOL & INFO SHEET



GLP PLUS+[™]

**Oral GLP-1 Receptor Agonism
Fatty Acid Oxidation · Metabolic Flexibility**

Orforglipron Metabolic Signaling Capsule



Clinical Abstract

GLP PLUS+ is an advanced oral metabolic signaling capsule combining Orforglipron – a small-molecule non-peptide GLP-1 receptor agonist – with a dual carnitine matrix designed to support fatty acid transport, mitochondrial energy utilization, and metabolic flexibility. Delivered via AgeREcode’s patent-pending enteric-coated multi-phase oral capsule platform, GLP PLUS+ is formulated for practitioner-guided metabolic optimization protocols where injectable administration is not preferred or indicated.

The formulation targets four key metabolic domains:

- 1. GLP-1 Receptor Pathway Activation** – Orforglipron engages GLP-1 receptors via a non-peptide, orally bioavailable small-molecule mechanism
- 2. Fatty Acid Oxidation & Transport** – Acetyl-L-Carnitine and L-Carnitine L-Tartrate facilitate mitochondrial uptake of long-chain fatty acids
- 3. Appetite & Satiety Signaling** – GLP-1 receptor engagement modulates central and peripheral appetite regulatory pathways
- 4. Glucose & Insulin Sensitivity Support** – Metabolic pathway modulation consistent with GLP-1 receptor agonism research

Clinical Indications

- Metabolic optimization and weight management protocols
- Patients seeking non-injectable GLP-1 pathway support
- Metabolic plateaus or weight loss resistance programs
- Appetite dysregulation and satiety management
- Adjunct to lifestyle, longevity, and cardiometabolic programs
- Practitioners exploring oral alternatives to injectable GLP-1 agents

Suggested Use

- 1 capsule each morning, on an empty stomach
- Allow 30–45 minutes before first meal
- Suggested cycle: 5 days on / 2 days off
- Practitioner supervision recommended; adjust based on patient response

Formulation (Per Capsule)

Active Ingredient	Amount	Primary Role
Acetyl-L-Carnitine	500 mg	Mitochondrial fatty acid transport; acetylcholine precursor; neuroprotective support
L-Carnitine L-Tartrate	200 mg	Enhanced carnitine bioavailability; exercise recovery; lipid metabolism support
Orforglipron	6 mg	Small-molecule oral GLP-1 receptor agonist; appetite regulation; glucose modulation

Other Ingredients: Vegan Capsule Shell, Magnesium Stearate, Silicon Dioxide, Mannitol.

Delivery: Size 00 HPMCAS enteric-coated capsule | Trehalose + Mannitol peptide stabilization matrix

Mechanism of Action Overview

Orforglipron is a non-peptide, small-molecule GLP-1 receptor agonist that binds and activates the GLP-1 receptor through allosteric mechanisms, mimicking the endogenous incretin hormone GLP-1. Unlike peptide-based GLP-1 agents that require injection, Orforglipron achieves oral bioavailability by leveraging its small-molecule architecture to survive gastric transit and absorb through the intestinal epithelium.

The dual carnitine matrix — Acetyl-L-Carnitine (ALCAR) and L-Carnitine L-Tartrate (LCLT) — works synergistically with GLP-1 pathway activation by facilitating the translocation of long-chain fatty acyl groups across the inner mitochondrial membrane, enhancing beta-oxidation and ATP yield. This pairing supports the metabolic shift toward fat utilization that GLP-1 receptor activation promotes, potentially amplifying energy substrate efficiency during caloric restriction.

Mechanism of Action Overview... Continued

Pathway	Active Agents	Mechanism
GLP-1 Receptor Activation	Orforglipron	Non-peptide allosteric GLP-1R agonism; oral bioavailability
Appetite / Satiety Signaling	Orforglipron	Central & peripheral GLP-1R-mediated satiety pathway modulation
Glucose Regulation Support	Orforglipron	GLP-1R-dependent insulin secretion signaling support
Fatty Acid Transport	Acetyl-L-Carnitine	Mitochondrial long-chain fatty acid translocation
Lipid Oxidation & Energy	L-Carnitine L-Tartrate	Enhanced beta-oxidation; carnitine pool repletion

Practitioner Applications

- **Weight Management Protocols** — Integrate as oral GLP-1 pathway support in structured weight loss programs
- **Metabolic Optimization Programs** — Support cardiometabolic health, body composition, and insulin sensitivity frameworks
- **Non-Injectable Patient Preference** — Oral option for patients resistant to or ineligible for injectable GLP-1 therapies
- **Appetite & Satiety Dysregulation** — Adjunct support for patients experiencing hyperphagia or poor satiety response
- **Longevity & Anti-Aging Protocols** — Incorporate into metabolic health and healthspan optimization regimens
- **Mitochondrial & Energy Support** — Leverage carnitine matrix for enhanced fatty acid oxidation alongside caloric restriction

Why Practitioners Are Exploring Oral Metabolic Signaling Platforms

- **Oral administration** — Eliminates injection-related barriers; improves patient adherence and acceptance
- **Small-molecule GLP-1 agonism** — Orforglipron achieves GLP-1R engagement without peptide degradation challenges
- **Carnitine metabolic synergy** — Dual carnitine matrix amplifies fat oxidation and energy efficiency
- **Protocol flexibility** — Can be titrated, cycled, or combined with existing metabolic protocols
- **Enteric-coated protection** — Multi-phase release system ensures targeted intestinal delivery

Stacking Synergy

- With REtone™ — GLP-1 tolerability support, lean mass preservation, thermogenesis
- With REvive™ — Cellular energy, NAD+, SIRT1 activation, mitochondrial axis
- With REcover™ — GI mucosal support, recovery optimization, tissue repair adjunct
- With REbalance™ — Hormonal axis optimization, cortisol regulation, sleep support

Manufacturing & Quality

- HPMCAS enteric-coated capsule (Size 00) — protects actives through gastric transit
- HPLC purity $\geq 99\%$ for all active ingredients | Trehalose + Mannitol stabilization matrix
- cGMP manufacturing | 24-month validated stability | Vegan capsule shell | Made in USA

Healthcare Professional Disclaimer: This document is intended for use by licensed healthcare professionals only. The information provided is for educational and informational purposes and is not intended to replace independent clinical judgment, diagnosis, or treatment decisions. GLP PLUS+ is provided for research and development use only. It is not a drug, medicine, supplement, or food. It is not intended to treat, diagnose, cure, or prevent any disease, ailment, or medical condition. These statements have not been evaluated by the Food and Drug Administration. Clinical application, patient selection, and dosing decisions are the sole responsibility of the treating healthcare provider. Published research and mechanistic data referenced herein relate to individual ingredients and biological pathways and do not constitute claims of clinical efficacy. Outcomes may vary based on patient factors, comorbidities, and concurrent therapies.